Zenbexus-led combination nabs FDA’s first CELMoD therapy approval in multiple myeloma

benzinga.com·Aug 14, 2026 · 1 g fa

Bristol Myers Squibb Gets FDA Nod For Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)

medpagetoday.com·Aug 13, 2026 · 2 g fa

FDA Approves First CELMoD Drug for Multiple Myeloma

morningstar.com·Aug 13, 2026 · 2 g fa

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

biopharmadive.com·Aug 14, 2026 · 2 g fa

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

endpoints.news·Aug 13, 2026 · 2 g fa

FDA approves Bristol Myers’ multiple myeloma successor

saudigazette.com.sa·Aug 12, 2026 · 4 g fa

SFDA becomes first regulatory authority globally to approve registration of 'ZENBEXUS' to treat multiple myeloma in adults

statnews.com·Aug 14, 2026 · 1 g fa

FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class